Allergan gets a win: FDA approves ubrogepant as cascade of treatments reshape migraine field
Two weeks after publishing successful Phase III trial data in the New England Journal of Medicine, Allergan has landed approval for their new acute migraine pain drug ubrogepant.
The drug, branded Ubrelvy, is the latest in a series of migraine drug approvals that have begun to reshape an often debilitating ailment the FDA estimates affects 37 million Americans. It is also a significant win for Allergan, who has been racing against Eli Lilly and Biohaven to develop similar pills to alleviate migraine pain.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.